Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (231-240 of 336) with videos related to

Pageof 34
Sort By:
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Clinical & Experimental Metastasis|September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 datasetAlessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Expert Review of Anticancer Therapy|April 5, 2023
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?Matilde Corianò, Diana Giannarelli, Giulia Scartabellati, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO NetworkGiuseppe Luigi Banna, Umberto Basso, Emilio Francesco Giunta, et al.
Biomedical Reports|January 14, 2020
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE studyMelissa Bersanelli, Elisabetta Lattanzi, Nunziata D'Abbiero, et al.
American Journal of Clinical Oncology|February 22, 2021
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7)Daniele Santini, Marco Stellato, Ugo De Giorgi, et al.
NPJ Precision Oncology|July 2, 2026
Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI studySara Elena Rebuzzi, Vanja Miskovic, Giuseppe Fornarini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLCGiulia Mazzaschi, Cristina Marrocchio, Lucas Moron Dalla Tor, et al.
European Urology|March 23, 2024
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 StudyRoberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, et al.
Oncotarget|March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinomaDaniele Santini, Matteo Santoni, Alessandro Conti, et al.
Pageof 34

Showing results (231-240 of 336) with videos related to

Sort By:
Pageof 34
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Clinical & Experimental Metastasis|September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 datasetAlessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Expert Review of Anticancer Therapy|April 5, 2023
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?Matilde Corianò, Diana Giannarelli, Giulia Scartabellati, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO NetworkGiuseppe Luigi Banna, Umberto Basso, Emilio Francesco Giunta, et al.
Biomedical Reports|January 14, 2020
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE studyMelissa Bersanelli, Elisabetta Lattanzi, Nunziata D'Abbiero, et al.
American Journal of Clinical Oncology|February 22, 2021
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7)Daniele Santini, Marco Stellato, Ugo De Giorgi, et al.
NPJ Precision Oncology|July 2, 2026
Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI studySara Elena Rebuzzi, Vanja Miskovic, Giuseppe Fornarini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLCGiulia Mazzaschi, Cristina Marrocchio, Lucas Moron Dalla Tor, et al.
European Urology|March 23, 2024
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 StudyRoberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, et al.
Oncotarget|March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinomaDaniele Santini, Matteo Santoni, Alessandro Conti, et al.
Pageof 34